BEYONDSPRING INC (BYSI) Stock Overview
USA - NASDAQ:BYSI - KYG108301006 - Common Stock
BYSI Key Statistics, Chart & Performance
The current stock price of BYSI is 1.9 USD. In the past month the price increased by 14.2%. In the past year, price decreased by -11.06%.
BYSI Latest News, Press Relases and Analysis
BYSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.08B | ||
| AMGN | AMGEN INC | 13.29 | 156.00B | ||
| GILD | GILEAD SCIENCES INC | 15.49 | 148.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.78 | 107.63B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.73 | 61.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.76B | ||
| ARGX | ARGENX SE - ADR | 89.53 | 50.77B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.09 | 34.63B | ||
| INSM | INSMED INC | N/A | 34.29B | ||
| NTRA | NATERA INC | N/A | 26.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.31B | ||
| BIIB | BIOGEN INC | 9.32 | 21.87B |
Related stock screener links
About BYSI
Company Profile
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Company Info
BEYONDSPRING INC
100 Campus Drive, West Side, 4Th Floor, Suite 410
Florham Park NEW JERSEY 10005 US
CEO: Lan Huang
Employees: 40
Phone: 16465284184
BEYONDSPRING INC / BYSI FAQ
What does BYSI do?
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
What is the current price of BYSI stock?
The current stock price of BYSI is 1.9 USD. The price decreased by -5.47% in the last trading session.
Does BYSI stock pay dividends?
BYSI does not pay a dividend.
What is the ChartMill rating of BEYONDSPRING INC stock?
BYSI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for BEYONDSPRING INC?
BEYONDSPRING INC (BYSI) operates in the Health Care sector and the Biotechnology industry.
What is the outstanding short interest for BEYONDSPRING INC?
The outstanding short interest for BEYONDSPRING INC (BYSI) is 6.16% of its float.
BYSI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BYSI. When comparing the yearly performance of all stocks, BYSI is a bad performer in the overall market: 72.8% of all stocks are doing better.
BYSI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BYSI. BYSI may be in some trouble as it scores bad on both profitability and health.
BYSI Financial Highlights
Over the last trailing twelve months BYSI reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 49.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.83% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |